A citation-based method for searching scientific literature

Gilles Salles, Franck Morschhauser, Thierry Lamy, Noel Milpied, Catherine Thieblemont, Hervé Tilly, Gabi Bieska, Elina Asikanius, David Carlile, Joe Birkett, Pavel Pisa, Guillaume Cartron. Blood 2012
Times Cited: 145

List of co-cited articles
957 articles co-cited >1

Times Cited
  Times     Co-cited

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt, Sylvia Herter, Roger Grau, Christian Gerdes, Adam Nopora, Erwin van Puijenbroek,[...]. Blood 2010

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
Laurie H Sehn, Sarit E Assouline, Douglas A Stewart, Joy Mangel, Randy D Gascoyne, Gregg Fine, Susan Frances-Lasserre, David J Carlile, Michael Crump. Blood 2012

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer,[...]. N Engl J Med 2014

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
Gilles A Salles, Franck Morschhauser, Philippe Solal-Céligny, Catherine Thieblemont, Thierry Lamy, Hervé Tilly, Emmanuel Gyan, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch,[...]. J Clin Oncol 2013

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang,[...]. Mol Cancer Ther 2013

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
Franck Andre Morschhauser, Guillaume Cartron, Catherine Thieblemont, Philippe Solal-Céligny, Corinne Haioun, Reda Bouabdallah, Pierre Feugier, Krimo Bouabdallah, Elina Asikanius, Guiyuan Lei,[...]. J Clin Oncol 2013

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J Cheadle, Sandeep Potluri, Sean H Lim, Kazuyuki Shimada, Claude H T Chan, Alison Tutt, Stephen A Beers,[...]. Blood 2011

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.
Gerhard Niederfellner, Alfred Lammens, Olaf Mundigl, Guy J Georges, Wolfgang Schaefer, Manfred Schwaiger, Andreas Franke, Kornelius Wiechmann, Stefan Jenewein, Jerry W Slootstra,[...]. Blood 2011

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
John Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo. Blood 2013

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger,[...]. Blood 2014

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Laurie H Sehn, Andre Goy, Fritz C Offner, Giovanni Martinelli, M Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D Zelenetz, Gianluca Gaidano, Luis E Fayad,[...]. J Clin Oncol 2015

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
M Hallek, K Fischer, G Fingerle-Rowson, A M Fink, R Busch, J Mayer, M Hensel, G Hopfinger, G Hess, U von Grünhagen,[...]. Lancet 2010

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein, Charles Dumontet. Mol Cancer Ther 2011

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, Hervé Watier. Blood 2002

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna, Josée Golay. J Immunol 2011

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas,[...]. J Clin Oncol 1998

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
Josée Golay, Fabio Da Roit, Luca Bologna, Claudia Ferrara, Jeanette H Leusen, Alessandro Rambaldi, Christian Klein, Martino Introna. Blood 2013

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
Michaela Patz, Polina Isaeva, Nche Forcob, Bianka Müller, Lukas P Frenzel, Clemens-Martin Wendtner, Christian Klein, Pablo Umana, Michael Hallek, Günter Krause. Br J Haematol 2011

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.
Jamie Honeychurch, Waleed Alduaij, Mahsa Azizyan, Eleanor J Cheadle, Helene Pelicano, Andrei Ivanov, Peng Huang, Mark S Cragg, Tim M Illidge. Blood 2012

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.
Mark S Cragg, Suzanne M Morgan, H T Claude Chan, B Paul Morgan, A V Filatov, Peter W M Johnson, Ruth R French, Martin J Glennie. Blood 2003

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Laurie H Sehn, Neil Chua, Jiri Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver Press, Gilles Salles,[...]. Lancet Oncol 2016

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
William G Wierda, Thomas J Kipps, Jirí Mayer, Stephan Stilgenbauer, Cathy D Williams, Andrzej Hellmann, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny,[...]. J Clin Oncol 2010

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
Robert Marcus, Kevin Imrie, Philippe Solal-Celigny, John V Catalano, Anna Dmoszynska, João C Raposo, Fritz C Offner, José Gomez-Codina, Andrew Belch, David Cunningham,[...]. J Clin Oncol 2008

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Stephen A Beers, Ruth R French, H T Claude Chan, Sean H Lim, Timothy C Jarrett, Regina Mora Vidal, Sahan S Wijayaweera, Sandra V Dixon, Hyungjin Kim, Kerry L Cox,[...]. Blood 2010

Rituximab dose-escalation trial in chronic lymphocytic leukemia.
S M O'Brien, H Kantarjian, D A Thomas, F J Giles, E J Freireich, J Cortes, S Lerner, M J Keating. J Clin Oncol 2001

Mechanisms of killing by anti-CD20 monoclonal antibodies.
Martin J Glennie, Ruth R French, Mark S Cragg, Ronald P Taylor. Mol Immunol 2007

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Frank Herting, Thomas Friess, Sabine Bader, Gunter Muth, Gabriele Hölzlwimmer, Natascha Rieder, Pablo Umana, Christian Klein. Leuk Lymphoma 2014

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Myron S Czuczman, Luis Fayad, Vincent Delwail, Guillaume Cartron, Eric Jacobsen, Kazimierz Kuliczkowski, Brian K Link, Lauren Pinter-Brown, John Radford, Andrzej Hellmann,[...]. Blood 2012

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles, John Francis Seymour, Fritz Offner, Armando López-Guillermo, David Belada, Luc Xerri, Pierre Feugier, Réda Bouabdallah, John Vincent Catalano, Pauline Brice,[...]. Lancet 2011

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser,[...]. Lancet 2013

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.
Andrei Ivanov, Stephen A Beers, Claire A Walshe, Jamie Honeychurch, Waleed Alduaij, Kerry L Cox, Kathleen N Potter, Stephen Murray, Claude H T Chan, Tetyana Klymenko,[...]. J Clin Invest 2009

Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Toshiki Uchida, Tatsuya Suzuki, Yukio Kobayashi, Masakazu Mori, Yasuhito Terui, Masahiro Yokoyama, Tomomitsu Hotta. Cancer Sci 2013

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
V Goede, K Fischer, A Engelke, R Schlag, S Lepretre, L F C Montero, M Montillo, C Fegan, E Asikanius, K Humphrey,[...]. Leukemia 2015

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
Jessica L Teeling, Wendy J M Mackus, Luus J J M Wiegman, Jeroen H N van den Brakel, Stephen A Beers, Ruth R French, Tom van Meerten, Saskia Ebeling, Tom Vink, Jerry W Slootstra,[...]. J Immunol 2006

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.
Robert L Shields, Jadine Lai, Rodney Keck, Lori Y O'Connell, Kyu Hong, Y Gloria Meng, Stefanie H A Weikert, Leonard G Presta. J Biol Chem 2002

CD20 as a target for therapeutic type I and II monoclonal antibodies.
Stephen A Beers, Claude H T Chan, Ruth R French, Mark S Cragg, Martin J Glennie. Semin Hematol 2010

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K Link, Tadeusz Robak, Marek Wojtukiewicz, Michael Pfreundschuh,[...]. Blood 2008

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Wojciech J Jurczak, Ian W Flinn, Christopher R Flowers, Peter Martin, Andreas Viardot,[...]. N Engl J Med 2014

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Guillaume Cartron, Florence Hourcade-Potelleret, Franck Morschhauser, Gilles Salles, Michael Wenger, Anna Truppel-Hartmann, David J Carlile. Haematologica 2016

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
Franck Morschhauser, John P Leonard, Luis Fayad, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Stephen J Schuster, Martin J S Dyer, Heather Horne, Nick Teoh,[...]. J Clin Oncol 2009

Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.
Sylvia Herter, Martina C Birk, Christian Klein, Christian Gerdes, Pablo Umana, Marina Bacac. J Immunol 2014

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Bertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, Ole Gadeberg, Henrik Fredriksen, Marinus H J van Oers, James Wooldridge, Janusz Kloczko, Jerzy Holowiecki, Andrzej Hellmann,[...]. Blood 2008

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Ranjana H Advani, Joseph J Buggy, Jeff P Sharman, Sonali M Smith, Thomas E Boyd, Barbara Grant, Kathryn S Kolibaba, Richard R Furman, Sara Rodriguez, Betty Y Chang,[...]. J Clin Oncol 2013

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Sean H Lim, Andrew T Vaughan, Margaret Ashton-Key, Emily L Williams, Sandra V Dixon, H T Claude Chan, Stephen A Beers, Ruth R French, Kerry L Cox, Andrew J Davies,[...]. Blood 2011

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.